JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $18

Benzinga · 10/14 12:55
JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the price target from $16 to $18.